Pulmonary Fibrosis

Patients treated with NAL ER demonstrated a 75.1% decrease in daytime cough frequency and a 76.1% decrease in 24-hour cough frequency compared with placebo.

The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.

As the US tries to move on from the pandemic, patients with long COVID-19 are fighting to regain normalcy while clinicians improve care plans and researchers search for answers.

According to the systmatic review, motavizumab, nirsevimab, and palivizumab, are associated with significant reductions in RSV-related infections and hospitalizations without a significant increase in adverse events.